FREE Stock Alerts!
Get Our 100% Free
Featured Stock Alerts Newsletter.
Enter your e-mail address below:
|
|
|
|
Sign Up Today for our Free OTC Stock Alerts Newsletter. Free Market Analysis on the Fastest Growing Stocks producing the Highest Yields and News about Companies with the Highest Potential for Gains!
|
|
|
Click Here to Read the Featured Report about this Company
CHERRY HILL, N.J.--(BUSINESS WIRE)--Nuvilex, Inc. (OTC Bulletin Board: NVLX
- News
), announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has received its National Drug Code numbers (50107-100-00, 50107-200-00, and 50107-300-00), from the
Food and Drug Administration
(FDA) for its homeopathic flu remedy. A National Drug Code (NDC) is a universal identifier of any product that is to be marketed as a drug for human use within the United States. The Drug Listing Act of 1972 states that all registered drug establishments must provide to the FDA a current list of all drugs manufactured, prepared, propagated, compounded, or processed by the establishment for commercial distribution.
As a registered homeopathic medicine, Reme-Flu™ is intended for use at the onset of flu or flu-like symptoms and contains ingredients widely recognized to reduce and/or shorten flu or flu-like symptoms. Legacy Biotechnologies’ Syn-X9™ formulation enhances the body’s utilization of Reme-Flu's™ active ingredients.
With the issuance of the NDC for Reme-Flu™, Legacy Biotechnologies is now preparing to manufacture, market and sell Reme-Flu™ for the spring 2010 flu season. Further details on Legacy’s marketing plans will be forthcoming.
“Legacy Biotechnologies has undertaken the appropriate and necessary steps to register Reme-Flu™ with the FDA insuring that Reme-Flu™, its labeling and packaging meet FDA standards for homeopathic remedies,” stated Martin Schmieg, Chairman and CEO of Nuvilex, Inc. “The registration process for Reme-Flu™ was exacting and time consuming, but was necessary in order to ensure that Reme-Flu™ could legally enter the marketplace. We greatly appreciate Legacy Biotechnologies’ building, registering and launching Reme-Flu™ with a commitment to quality, performance and customer satisfaction.”
According to the FDA Code of Federal Regulations, registration of a drug establishment or drug wholesaler, or assignments of a registration number, or assignment of an NDC number, does not in any way denote approval of the firm or its products.
About Nuvilex, Inc.
Nuvilex, Inc. is an emerging healthcare consumer products company. The Company’s lead products include: Cinnergen™, which promotes a healthy glucose metabolism; Cinnechol™, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink®
, a permanent yet more easily removable tattoo ink. The Company’s complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink®
. In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit http://www.nuvilex.com/
for additional information on the Company.
Click Here to Read the Featured Report about this Company
Disclosure
OTCReporter.com and HotOTCChina.com are owned by Oceanic Consulting, LLC ("Oceanic") and Garden State Resources NJ, LLC ("Garden State"), both of which are New Jersey limited liability corporations (OTCReporter.com and Hot OTCChina.com and its owners, Oceanic and Garden State, and their affiliates, directors and officers and immediate family members are referred to in our Disclaimer as "OTCR" or "we" or "us" or "our"). Oceanic and Garden State are referred to herein collectively as the "LLC Companies" when the context of the statements pertain to compensation matters, including our "Compensation Disclosure" section that seeks to comply with Section 17(b) of the 1933 Act, as amended, which states that any person who disseminates publications or other communications (through interstate commerce) for consideration received or to be received, directly or indirectly, from an issuer, underwriter, or dealer, must disclose the receipt and amount, whether past or prospective, of such consideration. The LLC Companies contracted to receive and received twenty five thousand dollars from a non-affiliate third party shareholder of NVLX in return for OTCR’s services to publicly and electronically disseminate information pertaining to NVLX. It is imperative that all readers of the above Compensation Disclosure Section click on the link below to carefully review our Disclaimer in its entirety, which contains important information about penny stocks, our operations, the limited nature of the information presented in our publications and various risks attendant to the companies that we profile.
Click to read our disclaimer
 
|
